Orthocell (ASX:OCC) received a license from the Hong Kong Department of Health's Medical Device Division for its nerve collagen wrap product Remplir, according to a Monday Australian bourse filing.
The license allowing the company to sell the product in Hong Kong was originally expected to be granted in the fourth quarter.
The company intends to appoint a local on-the-ground specialist distributor to drive sales in Hong Kong, per the filing.
Orthocell's shares added over 3% in recent Monday trade.